Daiwa Securities Group Portfolio holdings
AUM
$27.1B
1-Year Return
23.24%
This Quarter Return
-14.79%
1 Year Return
+23.24%
3 Year Return
+64.59%
5 Year Return
+118.48%
10 Year Return
+210.79%
AUM
$13.1B
AUM Growth
-$2.86B
(-18%)
Cap. Flow
-$409M
Cap. Flow
% of AUM
-3.13%
Top 10 Holdings %
Top 10 Hldgs %
37.91%
Holding
1,480
New
51
Increased
642
Reduced
399
Closed
56
Top Buys
| 1 |
Mid-America Apartment Communities
MAA
|
+$164M |
| 2 |
Equinix
EQIX
|
+$79M |
| 3 |
Digital Realty Trust
DLR
|
+$77.9M |
| 4 |
Prologis
PLD
|
+$44.5M |
| 5 |
Realty Income
O
|
+$38.9M |
Top Sells
| 1 |
American Tower
AMT
|
+$268M |
| 2 |
VICI Properties
VICI
|
+$232M |
| 3 |
Essex Property Trust
ESS
|
+$83M |
| 4 |
Ventas
VTR
|
+$56.2M |
| 5 |
Global X E-commerce ETF
EBIZ
|
+$35.2M |
Sector Composition
| 1 | Real Estate | 60.77% |
| 2 | Technology | 8.81% |
| 3 | Healthcare | 4.18% |
| 4 | Consumer Discretionary | 3.61% |
| 5 | Financials | 3.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1076
Ultragenyx Pharmaceutical
RARE
$3.02B
| $16K | ﹤0.01% |
261
+62
| +31% | +$3.8K |
|
1077
Guardant Health
GH
$7.05B
| $15K | ﹤0.01% |
380
+83
| +28% | +$3.28K |
|
1078
Novavax
NVAX
$1.29B
| $15K | ﹤0.01% |
291
-3,705
| -93% | -$191K |
|
1079
Arrowhead Research
ARWR
$3.99B
| $14K | ﹤0.01% |
394
+89
| +29% | +$3.16K |
|
1080
Scotiabank
BNS
$79.4B
| $14K | ﹤0.01% |
235
| – | – |
|
1081
iShares MSCI Mexico ETF
EWW
$1.86B
| $14K | ﹤0.01% |
300
-200
| -40% | -$9.33K |
|
1082
Maravai LifeSciences
MRVI
$376M
| $14K | ﹤0.01% |
490
+106
| +28% | +$3.03K |
|
|
KRTX
1083
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $14K | ﹤0.01% |
111
+25
| +29% | +$3.15K |
|
|
MRTX
1084
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $14K | ﹤0.01% |
207
+46
| +29% | +$3.11K |
|
|
TPTX
1085
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $14K | ﹤0.01% |
185
+41
| +28% | +$3.1K |
|
1086
Cytokinetics
CYTK
$6.22B
| $13K | ﹤0.01% |
319
+74
| +30% | +$3.02K |
|
1087
Denali Therapeutics
DNLI
$2.14B
| $13K | ﹤0.01% |
458
+102
| +29% | +$2.9K |
|
1088
Vir Biotechnology
VIR
$713M
| $13K | ﹤0.01% |
493
+111
| +29% | +$2.93K |
|
1089
AbCellera Biologics
ABCL
$1.28B
| $11K | ﹤0.01% |
1,060
+238
| +29% | +$2.47K |
|
|
BPMC
1090
DELISTED
Blueprint Medicines
BPMC
| $11K | ﹤0.01% |
222
+50
| +29% | +$2.48K |
|
1091
Amicus Therapeutics
FOLD
$2.45B
| $11K | ﹤0.01% |
1,044
+231
| +28% | +$2.43K |
|
1092
Harmony Biosciences
HRMY
$1.91B
| $11K | ﹤0.01% |
220
+49
| +29% | +$2.45K |
|
1093
Legend Biotech
LEGN
$6.18B
| $11K | ﹤0.01% |
199
-4,517
| -96% | -$250K |
|
1094
PTC Therapeutics
PTCT
$4.63B
| $11K | ﹤0.01% |
266
+60
| +29% | +$2.48K |
|
1095
Beam Therapeutics
BEAM
$2.01B
| $10K | ﹤0.01% |
262
+63
| +32% | +$2.41K |
|
1096
Outfront Media
OUT
$3.12B
| $10K | ﹤0.01% |
598
-130
| -18% | -$2.17K |
|
1097
Pacira BioSciences
PCRX
$1.2B
| $10K | ﹤0.01% |
169
+39
| +30% | +$2.31K |
|
1098
Fate Therapeutics
FATE
$115M
| $9K | ﹤0.01% |
360
+81
| +29% | +$2.03K |
|
1099
Insmed
INSM
$30.8B
| $9K | ﹤0.01% |
445
+100
| +29% | +$2.02K |
|
1100
Zai Lab
ZLAB
$3.16B
| $9K | ﹤0.01% |
255
+50
| +24% | +$1.77K |
|